3-(苯甲酰基氨基)-2-甲基丙酸 | 43218-35-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-(苯甲酰基氨基)-2-甲基丙酸
• 英文名称: 3-(benzoylamino)-2-methylpropanoic acid
• 英文别名: 3-benzamido-2-methylpropanoic acid；β-benzoylamino-isobutyric acid；β-Benzoylamino-isobuttersaeure；3-(benzoylamino)-2-methylpropionic acid；d,l-β-benzoylamino-isobutyric acid；N-benzoyl-β-amino-isobutyric acid
• CAS: 43218-35-5
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: CCEBPEVKSYSXIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  乙醇 、 3-(苯甲酰基氨基)-2-甲基丙酸 在 三乙基氯硅烷 作用下， 反应 7.5h， 以100%的产率得到ethyl 3-(benzoylamino)-2-methylpropanoate
  参考文献：
  名称：

  A new enantioselective synthesis of β-amino acids

  摘要：

  Enantioselective hydrogenation of some alpha,beta -unsaturated nitriles and their corresponding methyl esters bearing a phthalimidomethyl substituent at the alpha -carbon using Rh-DuPHOS catalysts afforded beta -amino acid precursors with modest e.e.s of up to 48%. Hydrogenation of the alpha,beta -unsaturated methyl esters using a Ru-BINAP catalyst gave higher e.e.s of up to 84%. Method development for the determination of the enantiomeric excesses of these derivatives using chiral HPLC is also reported. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(01)00097-0
• 作为产物：
  描述：

  N-[(二甲基氨基)甲基]苯甲酰胺 在 sodium hydroxide 、 氢溴酸 、 甲苯 作用下， 生成 3-(苯甲酰基氨基)-2-甲基丙酸
  参考文献：
  名称：

  Hellmann; Haas, Chemische Berichte, 1957, vol. 90, p. 1357,1360

  摘要：

  DOI：

文献信息

• Catalytic Asymmetric Synthesis of Unprotected β²-Amino Acids
  作者：Chendan Zhu、Francesca Mandrelli、Hui Zhou、Rajat Maji、Benjamin List

  DOI：10.1021/jacs.1c00249

  日期：2021.3.10

  Importantly, both aromatic and aliphatic β2-amino acids can be obtained using this method. Mechanistic studies are consistent with the aminomethylation to proceed via silylium-based asymmetric counteranion-directed catalysis (Si-ACDC) and a transition state to explain the enantioselectivity is suggested on the basis of density functional theory calculation.

  我们在这里报告了一种可扩展的催化一锅法，用于对映体纯和未修饰的 β 2 -氨基酸。新开发的密闭imidodiphosphorimidate（IDPI）催化各种的广泛适用的反应双甲硅烷基烯酮缩醛与甲硅烷基化氨基甲基醚，接着通过水解后处理，得到游离β 2个以高收率，纯度，和对映选择性α-氨基酸。重要的是，使用这种方法可以获得芳香族和脂肪族 β 2氨基酸。机理研究与通过基于甲硅烷基的不对称反阴离子导向催化 (Si-ACDC) 进行的氨甲基化一致，并在密度泛函理论计算的基础上提出了解释对映选择性的过渡态。
• [EN] QUINOLINYL GLUCAGON RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS DE QUINOLINYLGLUCAGON
  申请人：PFIZER

  公开号：WO2013014569A1

  公开（公告）日：2013-01-31

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

  本发明提供了一种式I的化合物或其药用可接受的盐，其中R1、R2、R3、A1、A2、A3、B1、B2、B3和B4如本文所定义。已发现式I的化合物可作为胰高血糖素拮抗剂或逆拮抗剂。因此，式I的化合物及其药物组成物对于治疗由胰高血糖素介导的疾病、紊乱或症状是有用的。
• NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS
  申请人：Robl Jeffrey A.

  公开号：US20140080788A1

  公开（公告）日：2014-03-20

  Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R 3 , R 4 , R 4a , R 5a , R 5b , R 5c , R 5d , R 5e , R 6a , R 6b , and R 6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  本发明提供了一种公式I的新化合物：或其对映异构体、顺反异构体、互变异构体、前药或其盐，其中m、Q、T、U、V、环A、X、Y、R3、R4、R4a、R5a、R5b、R5c、R5d、R5e、R6a、R6b和R6c的定义如本文所述，这些化合物是TGR5 G蛋白偶联受体调节剂。 TGR5 G蛋白偶联受体调节剂在治疗、预防或减缓需要TGR5 G蛋白偶联受体调节剂治疗的疾病方面具有用途。因此，本公开还涉及包含这些新化合物的组合物以及使用任何这些新化合物或包含任何这些新化合物的组合物来治疗与TGR5 G蛋白偶联受体活性相关的疾病或病症的方法。
• Novel 19-nor-pregnahexaenes, process for the preparation thereof, and pharmaceutical compositions containing them
  申请人：Technobiotic Ltd.

  公开号：EP0000609A1

  公开（公告）日：1979-02-07

  19-Nor-pregnahexaenes of formula wherein A is hydrogen, lower alkyl, fluoro or fluoro- substituted methyl; R1 is hydrogen, lower alkyl, or an acyl radical of a carboxylic acid; W is (H,H); (H, lower alkyl); (H, α-OR2), with R2 being hydrogen or an acyl radical of a carboxylic acid; or - CHT, with T being hydrogen, lower alkyl, fluorine, or chlorine; Q is OR4, with R4 being hydrogen or an acyl radical of a carboxylic acid; hydrogen, provided W is (H,H) or (H, lower alkyl); or together with W represents a 16α, 17α-lower alkylidenedioxy grouping; Y is (H,H), (H,OH), or oxygen; Z is hydrogen, chlorine or bromine; R, is hydrogen or an acyl radical of a carboxylic acid; or OR3 together with Q represents an alkylidenedioxy or alkylorthoalkanoate grouping; and when Q is hydroxy and R3 is hydrogen, the 17a, 20; 20, 21-bismethylanedioxy derivatives thereof; These compounds are novel, with the exception of the 21-acetate and 3,21-diacetate of 19-nor-pregna- 1,3,5 (10), 6,8,14- hexanene-3,17a,21- triol-20-one, while pharmaceutical compositions containing the latter two compounds are also novel. The preparation of the novel compounds by three methods is described, in particular dehydrogenation in position 14 of appropriate 19-nor-pregna- 1,3,5(10), 6,8-pentaenes by DDq. Representative compounds of the inventions have been shown to exhibit antimitotic activity and, in particular, are useful in treating psoriasis.

  式中的 19-正regnahexaenes 其中 A 是氢、低级烷基、氟或氟取代的甲基； R1 是氢、低级烷基或羧酸酰基； W 是（H，H）；（H，低级烷基）；（H，α-OR2），其中 R2 是氢或羧酸酰基；或 - CHT，其中 T 是氢、低级烷基、氟或氯；Q 是 OR4，其中 R4 是氢或羧酸酰基；氢，条件是 W 是（H，H）或（H，低级烷基）；或与 W 一起代表 16α、17α-低级亚烷基二氧基基团； Y 是（H,H）、（H,OH）或氧； Z 是氢、氯或溴； R，是氢或羧酸酰基；或 OR3 与 Q 一起代表亚烷基二氧基或烷基正烷酸酯基团； 以及当 Q 为羟基且 R3 为氢时，其 17a、20；20、21-二烷基二氧基衍生物； 除了 19-去甲-1,3,5(10),6,8,14-己烯-3,17a,21-三醇-20-酮的 21-乙酸酯和 3,21-二乙酸酯之外，这些化合物都是新颖的，而含有后两种化合物的药物组合物也是新颖的。本发明介绍了通过三种方法制备新型化合物，特别是通过 DDq 在适当的 19-去氢-1,3,5(10),6,8-戊烯的第 14 位进行脱氢。本发明中具有代表性的化合物已被证明具有抗变态反应活性，特别是可用于治疗牛皮癣。
• Novel 1-aryl-2-acylamido-3-fluoro-1-propanols, their preparation and pharmaceutical compositions containing them
  申请人：SCHERING CORPORATION

  公开号：EP0014437A2

  公开（公告）日：1980-08-20

  Disclosed herein are novel D-(threo)-1-aryl-2-acylamido-3-fluoro-1-propanols of the general formula I and specified salts thereof, where R represents a specified alkyl, haloalkyl, halodeuteroalkyl, azidomethyl or methylsulfonylmethyl group, X and X' independently represent a hydrogen or halogen atom, a nitro, cyano or a substituted or unsubstituted phenyl group or represent a group R1(A)n in which group n is zero or 1, A is oxygen, sulfur, carbonyl, sulfinyl or sulfonyl and R is a specified lower alkyl, amino or lower alkyl amino group and Z is hydrogen or a specified acyl group. The novel compounds exhibit antibacterial activity and their use for this purpose is disclosed. Also disclosed are methods for the preparation of the novel compounds as well as certain novel intermediates therefor.

  本文公开了通式 I 的新型 D-(苏氨酰)-1-芳基-2-酰氨基-3-氟-1-丙醇及其特定盐类。 及其特定的盐，其中 R 代表特定的烷基、卤代烷基、卤代中性烷基、叠氮甲基或甲磺酰甲基，X 和 X'独立地代表氢原子或卤素原子、硝基、氰基或取代或未取代的苯基或代表基团 R1(A)n，其中基团 n 为 0 或 1，A 为氧、硫、羰基、亚砜基或磺酰基，R 为特定的低级烷基、氨基或低级烷基氨基，Z 为氢或特定的酰基。 这些新型化合物具有抗菌活性，其用途也已公开。此外，还公开了制备这些新型化合物及其某些新型中间体的方法。